Armistice Capital, LLC Supernus Pharmaceuticals, Inc. Transaction History

Armistice Capital, LLC

$6.02 Billion
Q3 2024

A detailed history of Armistice Capital, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 5,096,000 shares of SUPN stock, worth $199 Million. This represents 2.64% of its overall portfolio holdings.

Number of Shares

5,096,000

Previous 5,272,000 3.34%

Holding current value

$199 Million

Previous $141 Million 12.67%

% of portfolio

2.64%

Previous 1.83%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $4.54 Million - $6.19 Million	-176,000 Reduced 3.34%	5,096,000 $159 Million
Q2 2024 Aug 14, 2024	BUY	$25.99 - $33.85 $44.2 Million - $57.5 Million	1,700,000 Added 47.59%	5,272,000 $141 Million
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $29.2 Million - $37.9 Million	-1,078,000 Reduced 23.18%	3,572,000 $122 Million
Q4 2023 Feb 13, 2024	SELL	$22.72 - $29.68 $10 Million - $13.1 Million	-442,000 Reduced 8.68%	4,650,000 $135 Million
Q3 2023 Nov 14, 2023	BUY	$27.57 - $32.91 $1.54 Million - $1.84 Million	56,000 Added 1.11%	5,092,000 $140 Million
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $20.5 Million - $26.6 Million	686,000 Added 15.77%	5,036,000 $151 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $209,580 - $252,180	-6,000 Reduced 0.14%	4,350,000 $158 Million
Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $7.37 Million - $8.98 Million	-237,004 Reduced 5.16%	4,356,000 $155 Million
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $3.43 Million - $4.21 Million	-118,996 Reduced 2.53%	4,593,004 $155 Million
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $40.8 Million - $55.2 Million	1,612,000 Added 52.0%	4,712,000 $136 Million
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $29.5 Million - $34.1 Million	-1,036,000 Reduced 25.05%	3,100,000 $100 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $6.22 Million - $8.08 Million	236,000 Added 6.05%	4,136,000 $121 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $13.6 Million - $18.1 Million	576,000 Added 17.33%	3,900,000 $104 Million
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $2.35 Million - $2.92 Million	-88,000 Reduced 2.58%	3,324,000 $102 Million
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $7.05 Million - $9.18 Million	292,000 Added 9.36%	3,412,000 $89.3 Million
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $1.42 Million - $2.06 Million	-80,000 Reduced 2.5%	3,120,000 $78.5 Million
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $20 Million - $24.8 Million	992,000 Added 44.93%	3,200,000 $66.7 Million
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $13.5 Million - $19.7 Million	-792,000 Reduced 26.4%	2,208,000 $52.4 Million
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $18.6 Million - $31.8 Million	1,288,000 Added 75.23%	3,000,000 $54 Million
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $34.1 Million - $49.9 Million	1,712,000 New	1,712,000 $40.6 Million

Others Institutions Holding SUPN

# of Institutions

284

Shares Held

60.5M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.09B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Account

Armistice Capital, LLC Supernus Pharmaceuticals, Inc. Transaction History